Vulva cancer
diseaseOn this page
Also known as cancer of mammalian vulvamalignant mammalian vulva neoplasmmalignant neoplasm of mammalian vulvamalignant neoplasm of the vulvamalignant neoplasm of vulvamalignant neoplasm of vulva unspecifiedmalignant neoplasm of vulva, unspecifiedmalignant tumor of the vulvamalignant tumor of vulvamalignant tumour of the vulvamalignant tumour of vulvamalignant vulva neoplasmmalignant vulva tumormalignant vulva tumourmalignant vulvar neoplasmmalignant vulvar tumormalignant vulvar tumourmammalian vulva cancerneoplasm of vulvavulval cancer
Summary
Vulva cancer (MONDO:0001528) is a cancer (an umbrella term covering 8 Mondo subtypes) and 153 clinical trials. Top therapeutic interventions include indocyanine green acid form, bleomycin, and human papillomavirus, l1 protein virus like particles. A subtype of female reproductive organ cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 8 Mondo subtypes
- Clinical trials: 153
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vulva cancer |
| Mondo ID | MONDO:0001528 |
| MeSH | D014846 |
| DOID | DOID:1245 |
| ICD-10-CM | C51 |
| ICD-11 | 1530443809 |
| NCIT | C7502 |
| SNOMED CT | 363367000 |
| UMLS | C0375071 |
| MedGen | 91196 |
| GARD | 0027581 |
| Anatomy (UBERON) | UBERON:0000997 |
| Is cancer (heuristic) | yes |
Also known as: cancer of mammalian vulva · malignant mammalian vulva neoplasm · malignant neoplasm of mammalian vulva · malignant neoplasm of the vulva · malignant neoplasm of vulva · malignant neoplasm of vulva unspecified · malignant neoplasm of vulva, unspecified · malignant tumor of the vulva · malignant tumor of vulva · malignant tumour of the vulva · malignant tumour of vulva · malignant vulva neoplasm · malignant vulva tumor · malignant vulva tumour · malignant vulvar neoplasm · malignant vulvar tumor · malignant vulvar tumour · mammalian vulva cancer · neoplasm of vulva · vulval cancer (+3 more)
Disease family
This is a subtype of female reproductive organ cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › vulva cancer
Related subtypes (8): vaginal cancer, fallopian tube cancer, uterine cancer, adenocarcinofibroma, endometrioid adenocarcinoma, adenosarcoma, ovarian cancer, gestational choriocarcinoma
Subtypes (8): labium majus cancer, labia minora cancer, paraurethral gland cancer, vulvar melanoma, clitoris cancer, vulva sarcoma, vulvar carcinoma, mixed germ cell tumor of vulva
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Cisplatin | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bleomycin, Cadonilimab, Carboplatin, Lenvatinib, Paclitaxel, Pembrolizumab.
Clinical trials & evidence
Clinical trials
Clinical trials: 153.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 86 |
| PHASE2 | 33 |
| PHASE3 | 16 |
| PHASE1 | 13 |
| PHASE1/PHASE2 | 4 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06871787 | PHASE4 | NOT_YET_RECRUITING | Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery |
| NCT04422366 | PHASE3 | RECRUITING | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| NCT04895020 | PHASE3 | RECRUITING | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years |
| NCT06476639 | PHASE3 | NOT_YET_RECRUITING | A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer |
| NCT00003325 | PHASE3 | COMPLETED | Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva |
| NCT00006096 | PHASE3 | TERMINATED | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva |
| NCT00028951 | PHASE3 | COMPLETED | Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva |
| NCT00033605 | PHASE3 | COMPLETED | Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis |
| NCT00543543 | PHASE3 | COMPLETED | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) |
| NCT00577317 | PHASE3 | TERMINATED | Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer |
| NCT00898352 | PHASE3 | COMPLETED | Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes |
| NCT00943722 | PHASE3 | COMPLETED | A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) |
| NCT01047345 | PHASE3 | COMPLETED | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) |
| NCT02997553 | PHASE3 | COMPLETED | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery |
| NCT03158220 | PHASE3 | COMPLETED | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) |
| NCT04425291 | PHASE3 | COMPLETED | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| NCT05372016 | PHASE3 | COMPLETED | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| NCT02628067 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) |
| NCT03403465 | PHASE2 | ACTIVE_NOT_RECRUITING | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers |
| NCT04141449 | PHASE2 | ACTIVE_NOT_RECRUITING | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation |
| NCT04430699 | PHASE2 | ACTIVE_NOT_RECRUITING | Cisplatin+Pembrolizumab+RT in Vulvar Cancer |
| NCT04708470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
| NCT05076942 | PHASE2 | RECRUITING | Groningen International Study on Sentinel Nodes in Vulvar Cancer-III |
| NCT05395962 | PHASE2 | RECRUITING | Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer |
| NCT05639972 | PHASE1/PHASE2 | RECRUITING | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers |
| NCT05686226 | PHASE2 | RECRUITING | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers |
| NCT05903833 | PHASE2 | RECRUITING | Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy |
| NCT05932212 | PHASE2 | RECRUITING | AK104 for Recurrent or Metastatic Vulvar Cancer |
| NCT05979610 | PHASE2 | RECRUITING | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies |
| NCT06023862 | PHASE2 | RECRUITING | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) |
| NCT06677190 | PHASE2 | RECRUITING | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin |
| NCT06715592 | PHASE2 | ACTIVE_NOT_RECRUITING | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study |
| NCT07101848 | PHASE2 | NOT_YET_RECRUITING | A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER |
| NCT07290894 | PHASE2 | RECRUITING | Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 |
| NCT07433283 | PHASE1/PHASE2 | RECRUITING | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor |
| NCT07443475 | PHASE2 | RECRUITING | Electrochemotherapy for Recurrent Vulvar Cancer |
| NCT00014599 | PHASE2 | COMPLETED | Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva |
| NCT00068406 | PHASE2 | COMPLETED | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva |
| NCT00275353 | PHASE2 | COMPLETED | Effectiveness of an Individualized Symptom Education Program (ISEP) |
| NCT00381888 | PHASE2 | COMPLETED | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| INDOCYANINE GREEN ACID FORM | 4 | 5 |
| BLEOMYCIN | 4 | 2 |
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | 4 | 2 |
| TIVOZANIB | 4 | 2 |
| BELZUTIFAN | 4 | 1 |
| CICLOPIROX | 4 | 1 |
| DOSTARLIMAB | 4 | 1 |
| FONDAPARINUX SODIUM | 4 | 1 |
| NELFINAVIR | 4 | 1 |
| OCTREOTIDE ACETATE | 4 | 1 |
| BINTRAFUSP ALFA | 3 | 1 |
| CADONILIMAB | 3 | 1 |
| ENTINOSTAT | 3 | 1 |
| FIBRIN | 3 | 1 |
| TRIAPINE | 3 | 1 |
| EDODEKIN ALFA | 2 | 1 |
| CHEMBL4084635 | 0 | 1 |
| COD LIVER OIL | -1 | 1 |